Results of a phase 2 study of evorpacept (E, ALX148), cetuximab (C), and pembrolizumab (P) in patients with refractory microsatellite stable metastatic colorectal cancer (MSS CRC).

Authors
Category Primary study
JournalJ. Clin. Oncol.
Year 2024
This article has no abstract
Epistemonikos ID: de6f85599a852bb999e6ae4764d6ef7f779c6937
First added on: Jan 10, 2026